A Novel, Paresthesia-Free Spinal Cord Stimulation Waveform for Chronic Neuropathic Low Back Pain: Six-Month Results of a Prospective, Single-Arm, Dose-Response Study

Neuromodulation. 2023 Oct;26(7):1412-1423. doi: 10.1016/j.neurom.2023.06.007. Epub 2023 Jul 22.

Abstract

Objectives: The aim of this prospective, single-blinded, dose-response study was to evaluate the safety and efficacy of a novel, paresthesia-free (subperception) spinal cord stimulation (SCS) waveform designed to target dorsal horn dendrites for the treatment of chronic neuropathic low back pain (LBP).

Materials and methods: Twenty-seven participants with chronic neuropathic LBP were implanted with a commercial SCS system after a successful trial of SCS therapy. Devices were programmed to deliver the investigative waveform (100 Hz, 1000 μs, T9/T10 bipole) at descending stimulation perception threshold amplitudes (80%, 60%, 40%). Programs were evaluated at six, ten, and 14 weeks, after which participants selected their preferred program, with more follow-up at 26 weeks (primary outcomes). Participants were blinded to the nature of the programming. Pain score (visual analog scale [VAS]), Brief Pain Inventory (BPI), quality of life (EQ-5D-5L), and health status (36-Item Short Form [SF-36]) were measured at baseline and follow-ups. Responder rate, treatment satisfaction, clinician global impression of change, and adverse events (AEs) also were evaluated.

Results: Mean (± SD) baseline VAS was 72.5 ± 11.2 mm. At 26 weeks (n = 26), mean change from baseline in VAS was -51.7 mm (95% CI, -60.7 to -42.7; p < 0.001), with 76.9% of participants reporting ≥50% VAS reduction, and 46.2% reporting ≥80% VAS reduction. BPI, EQ-5D-5L, and SF-36 scores were all statistically significantly improved at 26 weeks (p < 0.001), and 100% of participants were satisfied with their treatment. There were no unanticipated AEs related to the study intervention, device, or procedures.

Conclusions: This novel, paresthesia-free stimulation waveform may be a safe and effective option for patients with chronic neuropathic LBP eligible for SCS therapy and is deliverable by all current commercial SCS systems.

Clinical trial registration: This study is registered on anzctr.org.au with identifier ACTRN12618000647235.

Keywords: Dorsal horn; low back pain; neuropathic pain; spinal cord stimulation; stimulation waveform.

Publication types

  • Clinical Trial

MeSH terms

  • Chronic Pain* / diagnosis
  • Chronic Pain* / therapy
  • Humans
  • Low Back Pain* / diagnosis
  • Low Back Pain* / therapy
  • Paresthesia / diagnosis
  • Paresthesia / therapy
  • Peripheral Nervous System Diseases*
  • Prospective Studies
  • Quality of Life
  • Spinal Cord
  • Spinal Cord Stimulation* / adverse effects
  • Spinal Cord Stimulation* / methods
  • Treatment Outcome